pinkribbonrow.org

Pink walk!

Make 👏🏽 #Oncology 👏🏽 Drugs 👏🏽 Easier 👏🏽 To 👏🏽 Say

VIDEO: ‘Beyond proud’: Family, friends unveil memorial to remember couple killed in Gorge shooting kiro7.com/news/local/vid…

IO improving pCR in HR pos BC. But pCR rate in both trials still less than 30%. So will this really change EFS? I would suggest that this may only be the case only in PDL-1 pos group. #bcsm #esmo2023 ⁦Sherene Loi, MD⁩

Outstanding discussion on Checkmate7FL & KEYNOTE-756 by Stephen Johnston. Impressive pCR results, but need to wait for survival endpoints to understand the ultimate benefit. And when we talk about PD-L1 exp, it’s key to understand the assay & thresholds.

SKB264 (MK-2870) TROP 2 ADC with belatecan topoI payload DAR 7.4: phase 2 of 5 mg/kg q2wk in mBC HR+ n=38 ORR 36.8% mPFS 11.1 mo 36% g3/4 neutropenia #ESMO23 OncoAlert #bcsm

Beautiful presentation by Nancy Lin, MD on OP-1250 (palezestrant) in HR+ mBC RP2D 42% >= 3L prior tx CBR 40% PFS 4.6 mo (5.6mo ESR1m) OncoAlert Dana-Farber’s Breast Oncology Center #ESMO23

Recommending a book, so well written - I am honored to claim that I know the author (to be accurate, the author’s family).

monarchE: ctDNA at baseline + 24 mo in a subset of pts Detection of ctDNA at baseline soon after completion of neo/adjuvant tx: 10/178 (5.6%) 3 of 10 cleared ctDNA + none recurred 7 of 10 had persistence + all recurred #SABCS23 OncoAlert #bcsm

IMP030: Adj chemo+/- atezo in stage 2/3 TNBC Median f/u 25 mo iDFS: HR 1.12, p=0.37 iDFS in PDL1+ HR 1.03 Why is there no benefit in the adjuvant setting? Is it PDL1 vs PD1 (unlikely given benefit in IMP031 preop)? Is it that there is no tumor in place? OncoAlert #SABCS23

HER2CLIMB-02: The addition of tucatinib to T-DM1 significantly improved PFS (9.5 vs 7.4 months, HR 0.76, p=0.016) in patients with HER2+ MBC. OS curves look reverted (HR 1.23), though immature. Significant increase in the rate of severe liver toxicities and diarrhea. Poll below👇

MONARCH3: AI +/- abemaciclib Final OS analysis Median follow-up 8.1 years 66.8 vs 53.7 mo Absolute Difference 13.1 mo Not statistically significant 23.3% progression free at 6 yrs on the abemaciclib arm @oncolaert #SABCS23

Glad to see Asian data!

SENOMAC: SNB +/- ALND in pts with up to 2 macromets n=2450 Median f/u 47 mo Median tumor size 20mm (6% T3) 85% had 1 macromet 34.3% with ENE 34.5% had additional LNs on ALND (if 1 SLN 31.3%, if 2 SLN 51.3%) No difference in 5 yr RFS 88.7% vs 89.7% #SABCS23 OncoAlert

Poll, how do you pronounce foci? foe-sye or foe-kye?

Our opinion piece in STAT highlighting the need for stronger implementation and broader access to HPV vaccination programs to end cervical cancer in the US and across the globe. Thank you Binay Shah, MD, MHA and Fengting Yan. MD, PhD, FACP. for co-authoring this.

A new moonshot to fight cervical cancer is missing something: only one of the sponsors is within reach of the WHO’s recommendation for protecting women. We can and must to better LINK HERE: statnews.com/2024/11/29/hpv… Beyond Trauma Foundation Binay Shah, MD, MHA Providence Swedish @swedish Sid Upadhyay

I will be speaking at the Best of Hematology and Breast Cancer 2025 on January 3-4, 2025 in Seattle. My talk will be on 'No' for the Hrt Debate You can register here: education.binayfoundation.org/Seattle-Hemato… 2

In this video, Fengting Yan, MD, PhD, (Fengting Yan. MD, PhD, FACP.) discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer. #bcsm hubs.li/Q03htJbS0